These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 21616632)
1. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. Zhao YF; Wang CR; Wu YM; Ma SL; Ji Y; Lu YJ Biomed Pharmacother; 2011 Jun; 65(3):151-6. PubMed ID: 21616632 [TBL] [Abstract][Full Text] [Related]
2. Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Ji Y; Ma SL; Zhang YP; Tang JJ; Wu YM; Lu YJ Anticancer Drugs; 2009 Oct; 20(9):832-7. PubMed ID: 19620837 [TBL] [Abstract][Full Text] [Related]
3. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Hotta K; Tabata M; Kiura K; Kozuki T; Hisamoto A; Katayama H; Takigawa N; Fujimoto N; Fujiwara K; Ueoka H; Tanimoto M Oncol Rep; 2007 Feb; 17(2):313-7. PubMed ID: 17203166 [TBL] [Abstract][Full Text] [Related]
4. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer. Wang H; Fei Z; Jiang H J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172 [TBL] [Abstract][Full Text] [Related]
5. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Han SY; Zhao MB; Zhuang GB; Li PP Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251 [TBL] [Abstract][Full Text] [Related]
6. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Tracy S; Mukohara T; Hansen M; Meyerson M; Johnson BE; Jänne PA Cancer Res; 2004 Oct; 64(20):7241-4. PubMed ID: 15492241 [TBL] [Abstract][Full Text] [Related]
7. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related]
8. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151 [TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885 [TBL] [Abstract][Full Text] [Related]
10. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374 [TBL] [Abstract][Full Text] [Related]
11. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577 [TBL] [Abstract][Full Text] [Related]
12. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
14. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Bae KM; Wang H; Jiang G; Chen MG; Lu L; Xiao L Cancer Res; 2007 Jul; 67(13):6053-63. PubMed ID: 17616661 [TBL] [Abstract][Full Text] [Related]
15. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Galetti M; Alfieri RR; Cavazzoni A; La Monica S; Bonelli M; Fumarola C; Mozzoni P; De Palma G; Andreoli R; Mutti A; Mor M; Tiseo M; Ardizzoni A; Petronini PG Biochem Pharmacol; 2010 Jul; 80(2):179-87. PubMed ID: 20363215 [TBL] [Abstract][Full Text] [Related]
16. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370 [TBL] [Abstract][Full Text] [Related]
17. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165 [TBL] [Abstract][Full Text] [Related]
18. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Ko JC; Wang LH; Jhan JY; Ciou SC; Hong JH; Lin ST; Lin YW Lung Cancer; 2009 Sep; 65(3):290-8. PubMed ID: 19157634 [TBL] [Abstract][Full Text] [Related]
19. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786 [TBL] [Abstract][Full Text] [Related]
20. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Sordella R; Bell DW; Haber DA; Settleman J Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]